A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
As the group looks to expand into immune thrombocytopenia, there are several reasons to be cautious.
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.